Cargando…
Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro
Oxaliplatin is a platinum-based antineoplastic drug commonly used for treating colorectal, gastric, and pancreatic cancer. However, it frequently causes peripheral neuropathy as dose-limiting toxicity and is lacking a strategy for prevention. Alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174301/ https://www.ncbi.nlm.nih.gov/pubmed/32317735 http://dx.doi.org/10.1038/s41598-020-62738-w |
_version_ | 1783524609092485120 |
---|---|
author | Shigematsu, Nao Kawashiri, Takehiro Kobayashi, Daisuke Shimizu, Shiori Mine, Keisuke Hiromoto, Shiori Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao |
author_facet | Shigematsu, Nao Kawashiri, Takehiro Kobayashi, Daisuke Shimizu, Shiori Mine, Keisuke Hiromoto, Shiori Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao |
author_sort | Shigematsu, Nao |
collection | PubMed |
description | Oxaliplatin is a platinum-based antineoplastic drug commonly used for treating colorectal, gastric, and pancreatic cancer. However, it frequently causes peripheral neuropathy as dose-limiting toxicity and is lacking a strategy for prevention. Alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, is an oral antidiabetic drug. Previous studies have shown that DPP-4 inhibitors have pleiotropic effects, including neuroprotection. In this study, we investigated the effects of alogliptin on oxaliplatin-induced peripheral neuropathy using in vitro and in vivo models. In PC12 cells, alogliptin attenuated neurite disorders induced by oxaliplatin and cisplatin. The repeated injection of oxaliplatin caused mechanical allodynia and axonal degeneration of the sciatic nerve in rats. These neuropathies were ameliorated by co-administration of alogliptin. Moreover, alogliptin did not attenuate tumor cytotoxicity of oxaliplatin in the cultured colon, gastric, or pancreatic cancer cell lines and tumor-bearing mice. These findings suggest that alogliptin may be beneficial for preventing oxaliplatin-induced peripheral neuropathy. |
format | Online Article Text |
id | pubmed-7174301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71743012020-04-24 Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro Shigematsu, Nao Kawashiri, Takehiro Kobayashi, Daisuke Shimizu, Shiori Mine, Keisuke Hiromoto, Shiori Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao Sci Rep Article Oxaliplatin is a platinum-based antineoplastic drug commonly used for treating colorectal, gastric, and pancreatic cancer. However, it frequently causes peripheral neuropathy as dose-limiting toxicity and is lacking a strategy for prevention. Alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, is an oral antidiabetic drug. Previous studies have shown that DPP-4 inhibitors have pleiotropic effects, including neuroprotection. In this study, we investigated the effects of alogliptin on oxaliplatin-induced peripheral neuropathy using in vitro and in vivo models. In PC12 cells, alogliptin attenuated neurite disorders induced by oxaliplatin and cisplatin. The repeated injection of oxaliplatin caused mechanical allodynia and axonal degeneration of the sciatic nerve in rats. These neuropathies were ameliorated by co-administration of alogliptin. Moreover, alogliptin did not attenuate tumor cytotoxicity of oxaliplatin in the cultured colon, gastric, or pancreatic cancer cell lines and tumor-bearing mice. These findings suggest that alogliptin may be beneficial for preventing oxaliplatin-induced peripheral neuropathy. Nature Publishing Group UK 2020-04-21 /pmc/articles/PMC7174301/ /pubmed/32317735 http://dx.doi.org/10.1038/s41598-020-62738-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Shigematsu, Nao Kawashiri, Takehiro Kobayashi, Daisuke Shimizu, Shiori Mine, Keisuke Hiromoto, Shiori Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro |
title | Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro |
title_full | Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro |
title_fullStr | Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro |
title_full_unstemmed | Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro |
title_short | Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro |
title_sort | neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174301/ https://www.ncbi.nlm.nih.gov/pubmed/32317735 http://dx.doi.org/10.1038/s41598-020-62738-w |
work_keys_str_mv | AT shigematsunao neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT kawashiritakehiro neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT kobayashidaisuke neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT shimizushiori neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT minekeisuke neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT hiromotoshiori neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT uchidamayako neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT egashiranobuaki neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro AT shimazoetakao neuroprotectiveeffectofalogliptinonoxaliplatininducedperipheralneuropathyinvivoandinvitro |